SBIR/STTR Research Award
Method for Discovering Novel Transcriptional Regulators
Award amount
$0Program and phase
STTR · Phase IAward year
2003Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CROSSLINK GENETICS CORPORATION
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): Regulation of gene expression by transcription factors is one of the most fundamental biological processes. The pharmaceutical manipulation of this process would open doors toward new approaches to treatment of cancer and other major diseases.
We aim to develop a novel, comprehensive technology for manipulation of gene expression based on synthetic analogues of eukaryotic transcription factors. The design and synthesis of these artificial transcription factors (ATFs) has been accomplished in Phase I by replacing functional domains of natural transcription factors with artificial chemical moieties. These ATFs have a remarkably high biological activity combined with novel properties resulting from their unique chemical composition and structure.
In Phase II we propose to develop ATF technology further and apply it to target selected human genes in their native, chromosomal setting in tissue culture cells. This will be achieved by using a combination of chemical, biochemical, genetic and genomic tools. The specific aims of this proposal are:
1) Expanding the repertoire of ATFs with new chemical moieties.
2) Developing a robust and rapid assay for testing of ATFs in human cell culture lines.
3) Demonstration of the ability of ATFs to target selected endogenous human genes in tissue culture.
Technology keywords
Not reported